Welcome to our dedicated page for Stereotaxis Ord SEC filings (Ticker: STXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stereotaxis, Inc. filings document an operating medical-technology company focused on robotic systems and instruments for minimally invasive endovascular intervention. Recent Form 8-K reports record operating and financial results, product and regulatory information included in earnings materials, and material-event disclosures.
The company’s SEC record also includes a definitive proxy statement covering annual-meeting and shareholder voting matters, governance, executive compensation, and director elections. Capital-structure filings describe common stock, shelf registration use, and an at-the-market sales agreement for working capital, research and development, and commercialization of the company’s innovation pipeline.
Stereotaxis, Inc. ownership filing by Lagoda Investment Management, L.P. Lagoda reports beneficial ownership of 4,350,400 shares of common stock as of March 31, 2026, representing 4.5% of the class. The filing cites 97,477,538 shares outstanding as of March 16, 2026 from the issuer's proxy statement. Lagoda's general partner structure and voting/dispositive authority are described, and the filing is signed by Jason A. Ozone on May 15, 2026.
Stereotaxis, Inc. reported the results of its May 14, 2026 Annual Meeting of Shareholders. A total of 97,477,538 common shares were entitled to vote, and Series A Convertible Preferred Stock carried 23,705,445 votes on an as-converted basis, for 121,182,983 total voting power. Quorum was achieved with 79,183,920 votes represented, about 65.34% of voting power.
Shareholders elected three Class I directors to serve until the 2029 annual meeting. David Benfer, Arun Menawat, and Myriam Curet each received between 49,544,105 and 52,711,903 votes for, with relatively low opposition. Shareholders also ratified Ernst & Young LLP as independent auditor for fiscal 2026 by 79,036,638 votes for versus 112,633 against and approved, on a non-binding basis, executive compensation with 52,143,334 votes for and 985,434 against.
Stereotaxis, Inc. reported a Q1 2026 net loss of $5.9M, similar to the prior year, as it continues investing in robotic cardiac and endovascular technologies. Revenue declined to $6.3M from $7.5M, with lower systems and disposable sales partly offset by higher service and accessories.
Operating expenses were $9.8M, roughly flat year over year, and basic and diluted net loss per share improved slightly to $0.06 from $0.07. Cash, cash equivalents, and restricted cash increased to $14.6M at March 31, 2026, helped by net proceeds of about $4.6M from an at-the-market stock offering.
The company signed an agreement on April 14, 2026 to acquire Robocath for $20.0M in cash and/or stock plus up to $25.0M in milestone-based contingent consideration, aiming to add mechanical robotic technology for interventional cardiology and neurointerventions. Stereotaxis also continues ramping its MAGiC and MAGiC Sweep catheters and faces macroeconomic, tariff, supply chain, and hospital capital spending headwinds while carrying an accumulated deficit of about $589.2M.
Stereotaxis, Inc. reported first quarter 2026 results alongside major strategic and regulatory milestones. Revenue was $6.3 million, down from $7.5 million in the prior-year quarter, with systems revenue of $1.3 million and recurring revenue of $5.0 million.
Gross margin was 60%, and the company posted an operating loss of $6.0 million and net loss of $5.9 million. Adjusted operating expenses were $6.7 million, roughly flat versus the prior year, and negative free cash flow was $3.5 million. Stereotaxis ended March 31, 2026 with $14.6 million in cash and no debt.
The company highlighted U.S. FDA approval of its MAGiC robotically-navigated catheter in January and Synchrony digital operating room system in April, both now in commercial use. It also signed a definitive agreement to acquire Robocath, expanding its robotic platform. Stereotaxis expects double-digit revenue growth in 2026, total revenue above $40 million, and third- and fourth-quarter revenue each above $10 million, supported by manufacturing ramps for GenesisX and MAGiC.
Stereotaxis, Inc. agreed to acquire 100% of French robotics company Robocath through a Share Sale Agreement. The company will deliver initial consideration valued at $20.0 million in cash, Stereotaxis common stock based on $2.00 per share, or a mix, subject to closing adjustments.
The sellers may also receive up to $25 million in earnout payments tied to one FDA regulatory milestone and two commercial sales milestones. Part of the stock consideration may instead be delivered as pre-funded warrants, and total stock issued for upfront and milestone consideration is capped at 19.9% of shares outstanding before closing under NYSE American rules.
Stereotaxis will provide Robocath interim financing via monthly bonds initially expected to total about €1,300,000. Closing is targeted for July 2026, subject to debt restructuring, French regulatory clearance, absence of blocking legal orders or material adverse effects, and other customary conditions, with an outside end date of December 31, 2026.
Stereotaxis, Inc. Chief Financial Officer Kimberly R. Peery received a grant of stock options for 40,000 shares of common stock. The options carry an exercise price of $1.87 per share and expire on April 11, 2036, functioning as compensation rather than an open‑market purchase.
According to the vesting terms, 25% of the options vest one year after the grant date, with the remaining 75% vesting monthly over the next three years. Following this grant, Peery directly holds 340,750 derivative securities in total.
Stereotaxis, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The amendment adds the signature and consent of its independent registered public accounting firm, Ernst & Young LLP, and corrects an exhibit number designation.
The amendment does not update other disclosures and should be read together with the original filing. Ernst & Young issued an unqualified opinion on the consolidated financial statements and identified a single critical audit matter related to systems revenue recognition, focusing on contracts with multiple performance obligations and the allocation of transaction prices.
Stereotaxis, Inc. is calling shareholders to its 2026 Annual Meeting on May 14, 2026, at its St. Louis headquarters. Shareholders will vote to elect three Class I directors through 2029, ratify Ernst & Young LLP as 2026 auditor, and approve executive pay by a non-binding advisory vote.
Holders of 97,477,538 common shares and 21,008 Series A Convertible Preferred shares, representing an aggregate 121,182,983 votes as of March 16, 2026, may vote. The proxy describes a largely independent board with a lead independent director, committee structures, and an executive pay program that emphasizes long-term equity incentives, including a low $60,000 base salary for the CEO and performance-based awards.
Stereotaxis, Inc. files a replacement shelf registration that carries forward $79,639,304 of unsold securities under Rule 415(a)(6) as replacement registration for the prior registration declared effective June 6, 2023. The filing establishes a shelf for up to $100,000,000 of securities, including an at-the-market sales agreement previously sized at $50,000,000.
The prospectus states that upon effectiveness the remaining $42,139,304 available under the prior sales agreement will be included in the Sales Agreement prospectus forming part of this registration statement. Shares outstanding were 97,248,936 as of February 28, 2026, provided here as a context figure.